• Biodesix’ Heinrich Roder Presents at 2013 Biomarker Summit

    March 18, 2013 Session Examines Use of Circulating Proteins to Define Novel Disease States Biodesix, Inc., a fully integrated molecular diagnostics company dedicated to personalizing medicine, today announced that Chief Technology Officer Heinrich Roder, DPhil will present at the 6th Oncology Biomarkers Conference as part of the 2013 Biomarker Summit taking place in San Francisco, March 20-22, 2013. Dr. Roder ... Read more
  • VeriStrat® Provides Oncologists with More Information to Personalize Therapy for Elderly Patients With Lung Cancer

    February 20, 2013 Data Published in Journal of Thoracic Oncology A new study published online ahead of print in the Journal of Thoracic Oncology concludes that Biodesix’ VeriStrat test was predictive of survival outcomes between erlotinib and gemcitabine. The study, “A Retrospective Analysis of VeriStrat Status on Outcome of a Randomized Phase II Trial of First-Line Therapy with Gemcitabine, Erlotinib, or the Combination in ... Read more
  • VeriStrat® Test Predicts Differential Treatment Benefit between Chemotherapy and Targeted Therapy for Lung Cancer Patients

    September 6, 2012 Encouraging New Data Presented at Chicago Multidisciplinary Symposium in Thoracic Oncology Results from the VeriStrat analysis of serum or plasma samples taken from a Phase II study evaluating erlotinib, gemcitabine, and erlotinib plus gemcitabine in elderly advanced NSCLC patients were presented today  at the Chicago Multidisciplinary Symposium  in Thoracic Oncology. The retrospective analysis showed that the VeriStrat test was ... Read more
  • Biodesix Closes Series D Financing

    August 29, 2012 Biodesix, Inc., a fully integrated molecular diagnostic company dedicated to personalizing medicine, has closed on a $12 million extension to its Series D financing. The new capital will support commercialization activities for the Company’s first product VeriStrat®, a blood-based test that helps physicians guide treatment for patients with non-small cell lung cancer (NSCLC).  Funding will also ... Read more
  • Biodesix Announces New VeriStrat® Data to be Presented at the 2012 Chicago Multidisciplinary Symposium in Thoracic Oncology

    August 23, 2012 Biodesix today announced that VeriStrat results from two phase II advanced lung cancer trials will be presented at the upcoming 2012 Chicago Multidisciplinary Symposium in Thoracic Oncology. The first study will be presented by Karen Reckamp, MD (City of Hope Comprehensive Cancer Center) and reports on the analysis of pre-treatment serum samples from a Phase II study evaluating ... Read more
  • Biodesix Appoints Vice President of Clinical Development & Medical Affairs

    July 17, 2012 Biodesix, Inc., a fully integrated molecular diagnostic company dedicated to personalizing medicine, today announced the appointment of Dominic Spinella, Ph.D., as Vice President of Clinical Development & Medical Affairs. Rounding out the management team, Dr. Spinella joins Biodesix to provide leadership for all clinical development operations. He will be based in the company’s Boulder, CO ... Read more
  • Biodesix’ Proteomic Analysis of Innovative Immunotherapy Clinical Trial in Pancreas Cancer presented at European Society of Medical Oncology’s (ESMO) World Congress on Gastrointestinal Cancer

    June 27, 2012 Biodesix, Inc., a fully integrated molecular diagnostic company dedicated to personalizing medicine, today announced the presentation of initial results of their proteomic analysis of GlobeImmune’s Phase 2 clinical trial in pancreas cancer at the European Society of Medical Oncology’s, 14th World Congress on Gastrointestinal Cancer in Barcelona, Spain on 27 June 2012. This marks the ... Read more
  • Biodesix’ Paul Beresford Joins 2012 BIO Panel for Personalized Medicine Commercialization

    June 6, 2012 Line Up Includes Beresford, Industry Veterans from Roche, AstraZeneca and Life Technologies Biodesix, Inc., a fully integrated molecular diagnostics company dedicated to personalizing medicine, today announced that Paul Beresford, Ph.D., Vice President of Business Development and Strategic Marketing, will join industry veterans on a panel discussing the recipe for the successful commercialization of personalized medicine at the 2012 ... Read more
  • VeriStrat® Test Results Correlate with Survival Outcomes in Advanced Lung Cancer

    April 23, 2012 Results from the combined analysis of two European Phase II trials were presented today at the 3rd European Lung Cancer Conference in Geneva, Switzerland. The VeriStrat retrospective analysis was performed on serum samples from advanced non-squamous non-small cell lung cancer (NSCLC) patients treated with the combination therapy bevacizumab plus erlotinib. Results showed that the VeriStrat ... Read more
  • Biodesix Announces Phase 3 Clinical Trial Collaboration with Kadmon

    February 27, 2012 Biodesix Inc., a fully integrated molecular diagnostic company dedicated to personalizing medicine, today announced a collaboration with Kadmon Corporation, LLC, to explore the utility of Biodesix’ VeriStrat® test in a Phase 3 non-small cell lung cancer (NSCLC) study of Kadmon’s KD019, a reversible tyrosine kinase inhibitor (TKI) targeting EGFR, HER2, VEGFR2 & 3, and SRC. The Phase 3 ... Read more